Read the News and Earn Credit - Click for Credit

For news and views that matter to gastroenterologist
Click here »

Achieving Remission in IBD Looking to Novel Agents to Update Management Paradigms

Bookmark and Share

A CME-Certified Supplement to GI & Hepatology News is jointly provided by Global Education Group/UMA and Strategic Consultants and supported by an educational grant from Takeda Pharmaceuticals International, Inc. US, Region.

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region.


Stephen B. Hanauer, MD
Professor of Medicine
Feinberg School of Medicine
Medical Director, Digestive Disease Center
Northwestern Medicine
Chicago, IL

Dermot McGovern, MD, PhD, FRCP
Professor of Medicine
Director, Translational Research
F Widjaja Foundation Inflammatory
Bowel and Immunobiology Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA

David T. Rubin, MD
Professor of Medicine
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, Illinois

Bruce E. Sands, MD
Dr. Burrill B. Crohn Professor of Medicine
Chief, Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY

>> Back to Top

Topic Highlights

  • Defining the Burden of IBD
  • Management Strategies in IBD: Where Are We Now?
  • Disease Mechanisms and Therapeutic Targets
  • Integrins and Addressins in IBD: Examining the Evidence

>> Back to Top

Target Audience

This educational activity addresses the needs of gastroenterologists involved in the treatment of patients with inflammatory bowel disease (IBD).

>> Back to Top

Educational Needs

For patients with moderate or moderate to severe IBD, therapeutic options are limited to immunosuppressive therapy or biologic therapy with anti–tumor necrosis factor-alpha (TNF-α) agents. Although these can be effective, a significant proportion of patients with IBD are primary nonresponders to anti-TNF-α therapy, and more than one-half of responders experience loss of response or suffer side effects. Therefore, there is a clearly defined unmet need for novel treatments with different targets, ideally that are more "gastrointestinally selective". Available clinical data suggest that integrin inhibitors could offer one such option in the future. This activity will review current best practice and unmet needs as well as the information that underpins the rationale for integrin inhibition. The current clinical evidence will be discussed, focusing on how these agents may be part of future clinical management of IBD.

>> Back to Top

Learning Objectives

After completing this activity, the participant should be able to:

  • Summarize the role of lymphocytes in the pathogenesis of IBD and the shared pathophysiology of ulcerative colitis (UC) and Crohn's disease (CD)
  • Explain the efficacy and limitations of current therapyfor moderate to severe IBD and the impact of unmet medical needs
  • Review the identification of treatment failure and the options available for patients who do not respond to current therapy
  • Describe the mechanism of action of integrin inhibitors in IBD and how integrin inhibitors could be integrated into clinical care paradigms for IBD.

>> Back to Top


Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Stephen B. Hanauer, MD: Consultant: AbbVie, Amgen, Elan, Genentech, GlaxoSmithKline, Janssen, Millennium, Pfizer, Prometheus, Salix, Santarus, Shire, Takeda, UCB Pharma, Warner Chilcott; Clinical Research: AbbVie, Amgen, Elan, Genentech, GlaxoSmithKline, Janssen, Millennium, Pfizer, Prometheus, Salix, Shire, Takeda, UCB Pharma, Warner Chilcott.

David T. Rubin, MD: Consultant: AbbVie/Abbott Immunology, Bristol-Myers Squibb, Centocor/Janssen, Elan, Emmi, Given Imaging, Ironwood, Lifecore Biomedical, Prometheus, Santarus, Takeda-Millennium, Telsar Pharma, UCB Pharma, Vertex; Grant Support: Abbvie/Abbott Immunology, Elan, Prometheus, Shire, Warner Chilcott; Other: Cornerstones Health, Inc.(co-founder, nonprofit medical education entity).

Dermot P. McGovern, MD, PhD, FRCP: Honoraria: Ironwood.

Bruce E. Sands, MD: Consulting: Abbott Immunology, Amgen, Dainippon Sumitomo Pharma, PureTech Ventures, Resolvyx, Sigmoid Biotechnologies, Takeda; Consultant (service on a scientific advisory board): Avaxia Biologics, Baxter, Bristol-Myers Squibb, Elan, Janssen Biotech, Luitpold Pharmaceuticals, Millennium, Pfizer, Teva; Research Grants: Abbott Immunology, Amgen, GlaxoSmithKline, Janssen Biotech, Pfizer, Prometheus, Takeda; Other: Avaxia Biologics (shares in a nonpublicly traded company).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ian Morgan, MSc, Elena Urso, BSc, Amanda Glazar, PhD, and Ashley Marostica, RN, MSN have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Strategic Consultants International do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

>> Back to Top

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Strategic Consultants International. Global is accredited by the ACCME to provide continuing medical education for physicians.

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Physician Credit Designation

Global Education Group designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

>> Back to Top

Term of Approval

Release date: February 12, 2014
Expiration date: February 28, 2015
Estimated time to complete activity:
0.5 hour

Copyright © 2014 Global Academy for Medical Education LLC.

>> Back to Top

click me